GCGR

Glucagon Receptor

GCGR

Related Products

GCGR (glucagon receptor) is in the G protein-coupled receptor family, that is important in controlling blood glucose levels. The glucagon receptor is a 62 kDa protein that is activated by glucagon and is a member of the class B G-protein coupled family of receptors, coupled to G alpha i, Gs and to a lesser extent G alpha q. Stimulation of the receptor results in activation of adenylate cyclase and increased levels of intracellular cAMP. In humans, the glucagon receptor is encoded by the GCGR gene. Glucagon receptors are mainly expressed in liver and in kidney with lesser amounts found in heart, adipose tissue, spleen, thymus, adrenal glands, pancreas, cerebral cortex, and gastrointestinal tract.

GCGR Related Products (179)
Recombinant Proteins (10)
Antibodies (3)

By Effects:	Controls (4) Inhibitors (10) Agonists (88) Antagonists (32) Modulators (8)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-19947

PF-06291874	Antagonist	99.31%
PF-06291874 is a highly potent, non-peptide and orally active glucagon receptor antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM).

HY-P0082A

Glucagon (1-29), bovine, human hydrochloride		99.89%
Glucagon (1-29), bovine, human, porcine hydrochloride is a peptide hormone, produced by pancreatic α-cells. Glucagon hydrochloride stimulates gluconeogenesis. Glucagon (1-29), bovine, human, porcine hydrochloride activates HNF4α and increases HNF4α phosphorylation.

HY-P99357

Crotedumab	Inhibitor	99.94%
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a K_D of 0.1 nM. Crotedumab can be used for the research of diabetes.

HY-P2231

Cotadutide	Agonist	99.11%
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D).

HY-P3101

GLP-1(28-36)amide		98.64%
GLP-1(28-36)amide, a C-terminal nonapeptide of GLP-1, is a major product derived from the cleavage of GLP-1 by the neutral endopeptidase (NEP). GLP-1(28-36)amide is an antioxidant and targets to mitochondrion, inhibits mitochondrial permeability transition (MPT). GLP-1(28-36)amide has anti-diabetic and cardioprotection effects.

HY-P2625

GLP-2(3-33)	Agonist	99.82%
GLP-2(3-33), generated naturally by dipeptidylpeptidase IV (DPPIV), acts as a partial agonist on GLP-2 receptor (EC₅₀=5.8 nM).

HY-112185A

Orforglipron hemicalcium hydrate	Agonist	99.71%
Orforglipron hemicalcium hydrate (LY3502970 hemicalcium hydrate; GLP-1 receptor agonist 1 hemicalcium hydrate) is the calcium salt hydrate form of Orforglipron (HY-112185). Orforglipron is an orally active agonist for Glucagon-like peptide-1 receptor (GLP-1R), which exhibits potency in ameliorating the type 2 diabete.

HY-P0150

Glucagon (19-29), human	Inhibitor	99.11%
Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.

HY-P4146A

Survodutide TFA	Agonist	99.39%
Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC₅₀s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake.

HY-P1348

GLP-1 moiety from Dulaglutide		99.59%
GLP-1 moiety from Dulaglutide is a 31-amino acid fragment of Dulaglutide. GLP-1 moiety from Dulaglutide is a glucagon-like peptide 1 receptor (GLP-1) agonist. Dulaglitude can be used in researches of diabetes and myocardial injury.

HY-P99383

Volagidemab	Antagonist	≥99.0%
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D).

HY-50159

Glucagon receptor antagonist-3	Antagonist	99.78%
Glucagon receptor antagonist-3 is a highly potent glucagon receptor antagonist.

HY-P0014S1

Liraglutide-¹³C₅,¹⁵N TFA	Agonist	98.19%
Liraglutide-¹³C₅,¹⁵N (tetraTFA) is the ¹³C and ¹⁵N labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.

HY-P1145A

Glucagon-like peptide 1 (1-37), human TFA	Agonist	98.09%
Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor.

HY-P3366

Ecnoglutide	Agonist	98.61%
Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-like peptide 1 (GLP-1) receptor agonist. Ecnoglutide can be used for research of T2DM and obesity.

HY-103547

L-168049	Antagonist	99.93%
L-168049 is a potent, selective, orally active and non-competitive glucagon receptor antagonist with IC₅₀s of 3.7 nM, 63 nM, and 60 nM for human, murine, and canine glucagon receptors, respectively.

HY-P3102

GLP-1(32-36)amide		98.44%
GLP-1(32-36)amide, a pentapeptide, derived from the C terminus of the glucoregulatory hormone GLP-1. GLP-1(32-36)amide could inhibit weight gain and modulate whole body glucose metabolism in diabetic mice.

HY-141840

GLP-1R modulator C5	Modulator	99.60%
GLP-1R modulator C5 is an allosteric modulator enhancing GLP-1 binding to GLP-1R via a transmembrane site (EC₅₀ 1.59 ± 0.53 μM).

HY-141842

GLP-1R modulator L7-028	Modulator	98.77%
GLP-1R modulator L7-028 is an allosteric modulator enhancing GLP-1 binding to GLP-1R via a transmembrane site (EC₅₀ 11.01 ± 2.73 μM).

HY-141839

GLP-1R modulator C16	Modulator	99.60%
GLP-1R modulator C16 is an allosteric modulator enhancing GLP-1 binding to GLP-1R via a transmembrane site (EC₅₀ 8.43 ± 3.82 μM).

Name
Email *

	Sorry, but the email address you supplied was invalid.

GCGR

GCGR

GCGR Related Products (179)

Recombinant Proteins (10)

Antibodies (3)

GCGR Related Products (179):